Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding.

"This is a good opportunity for Omeros and represents a potential life-saving treatment for patients. With the withdrawal of Trasylol® from the market in 2008, there is an immediate need for a safe and effective antifibrinolytic," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The ex vivo human and in vivo animal efficacy data look strong, and the regulatory pathway is well-defined. We have begun IND-enabling activities and are working to advance the program quickly to the clinic."

Excessive bleeding during cardiac surgery is known to increase overall morbidity and mortality. In an attempt to control this bleeding, patients undergoing cardiac and other extensive surgery often receive antifibrinolytic compounds. Until its permanent withdrawal from the market in 2008, the antifibrinolytic Trasylol® (aprotinin) had been shown in a number of studies to be more effective at reducing blood loss than the other two commonly used agents, tranexamic acid (TXA) and epsilon aminocaproic acid (EACA). Though effective, Trasylol® had a number of limitations. It was a bovine protein that was associated with anaphylactic reactions. Further, Trasylol® was non-selective and inhibited many proteins in addition to plasmin, including Factor XIa and kallikrein, important regulators of the coagulation cascade. Trasylol® was permanently withdrawn from the market after its use was found to be associated with increased mortality. While the specific cause of this increase remains unknown, an often-cite
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
... Reportlinker.com announces that a new market research ... Merck & Co., Inc.: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast performance ... sector. The profile encompasses global company strategy, portfolio ...
Cached Medicine Technology:Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... The ... concern among both men and women often causing pain and discomfort. Those who spend ... this circulatory problem, and Northeast Houston Vein Center is doing what it can to ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of the ... HOPE Movement of EvolvHealth. In what has been a long-term relationship between the companies ... missions of purpose together to change the course of the network marketing industry. , ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, ... free to download on the Apple AppStore. , The app is designed to ... thus acting as a tool to view personal health and use this information for ...
(Date:8/1/2015)... ... ... 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) ... Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles in ... friends and family. He visited CCAR and left an inspirational message to his staff: ...
(Date:7/31/2015)... ... 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, such ... sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both ... this new type of sod, Super-Sod is giving away red Adirondack chairs with the ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... study suggests that extra iron for infants who don,t need ... over optimal iron supplement levels and could have huge implications ... for 25 years of research show problems with lack of ... deal, it,s really unexpected," said Dr. Betsy Lozoff, University of ...
... Actress Joins Thousands of Participants in Inspirational Closing ... Local Breast Cancer Organizations, WASHINGTON, May 4 ... Foundation Reese Witherspoon was a special guest at ... D.C. this weekend,cheering on and joining walkers on ...
... 2008 Annual Meeting in San,Diego, CA, NEW YORK, ... MD, is the new President of the American Society ... 2,400,members, is the leading national organization of board-certified plastic,surgeons ... The,election of new officers was held on May 4, ...
... parents have a surprisingly low-level knowledge of typical ... physical, social and emotional growth, according research from ... suggest that such false parenting assumptions can not ... of much-needed cognitive stimulation, will be presented Sunday, ...
... always connected, researchers say , , FRIDAY, May 2 (HealthDay ... experienced by Alzheimer,s disease patients and the sleep woes ... from the University of Washington, in Seattle, found that ... always connected. , The researchers studied 44 older adults, ...
... Ripping out and tearing down to create a divinely ... and the economic downturn may be leading more families ... has found that parents need to be aware that all ... due to exposure to lead. , The study ...
Cached Medicine News:Health News:Iron supplements might harm infants who have enough 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Long Island Plastic Surgeon is New President of American Society for Aesthetic Plastic Surgery 2Health News:Long Island Plastic Surgeon is New President of American Society for Aesthetic Plastic Surgery 3Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Sleep Troubles Vary Between Alzheimer's Patients, Caregivers 2Health News:Fixing up 'this old house' may increase young 2Health News:Fixing up 'this old house' may increase young 3
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting...
Medicine Products: